Clinical Trials
10 trialsNCT03576378 2024-02-26
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Unknown
NCT03077828 2023-06-02
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT04981899 2023-04-12
NICE-40
St. Petersburg State Pavlov Medical University
Phase 1/2 Unknown
NCT03315520 2018-05-22
BeEAC-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Phase 2 Unknown
NCT00795613 2015-10-19
HD0607
Ospedale Santa Croce-Carle Cuneo
Phase 2 Unknown
NCT00002987 2013-12-04
Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00003262 2013-09-20
Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00041210 2013-09-20
Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00025636 2013-09-17
Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00908180 2013-08-02
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown